Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial is a research paper published in PLoS Medicine (2024). On theSindex it has a DataRank of 0.438. It has been cited 16 times, with 8 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.425
From this paper's citation signal
Citation Network Contribution
0.0132
From 3 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 8 citers.
National Institute of Allergy and Infectious Diseases
Grant: AI068614
National Institute of Allergy and Infectious Diseases
Grant: UM1 AI068635
National Institute of Allergy and Infectious Diseases
Grant: UM1 AI068618
National Institute of Allergy and Infectious Diseases
Grant: UM1 AI069412
National Center for Advancing Translational Sciences
Grant: UL1 RR025758
National Institute of Allergy and Infectious Diseases
Grant: P30 AI50410
National Institute of Allergy and Infectious Diseases
Grant: UM1 AI069423
National Institute of Allergy and Infectious Diseases
Grant: UM1 AI068619
National Institute of Allergy and Infectious Diseases
Grant: UM1 AI068617
National Institute of Allergy and Infectious Diseases
Grant: UM1 AI068613
National Center for Advancing Translational Sciences
Grant: UM1 TR004406
NIAID NIH HHS
Grant: U01 AI069470
NIAID NIH HHS
Grant: UM1 AI068614
NIAID NIH HHS
Grant: U01 AI068614
NIAID NIH HHS
Grant: P30 AI050410
NIAID NIH HHS
Grant: UM1 AI069470
National Institutes of Health
Grant: 3UL1RR025758-04S1
Harvard Clinical and Translational Science Center (UL1)
National Institutes of Health
Grant: 5UM1AI068619-09
LOC: HIV Prevention Trials Network
National Institutes of Health
Grant: 3UM1AI068635-17S4
CoVPN 3001 - A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults.
National Institutes of Health
Grant: 3UM1AI068617-20S1
HPTN SDMC: HPTN 096 Getting to Zero among Highest HIV Incidence (HHI) Men who have Sex with Men (MSM) in the American South: Testing an Integrated Strategy
National Institutes of Health
Grant: 5UM1TR004406-02
North Carolina Translational and Clinical Sciences Institute (NC TraCS)
National Institutes of Health
Grant: 5UM1AI068613-16
LC: HIV PREVENTION TRIALS NETWORK
National Institutes of Health
Grant: 5P30AI050410-05
UNC Center for Aids Research
National Institutes of Health
Grant: 5UM1AI069423-18
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit
National Institutes of Health
Grant: 3UM1AI068618-16S1
HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3
National Institutes of Health
Grant: 2UM1AI069412-08
Harvard/Boston/Providence Clinical Trials Unit (Harvard/B/P CTU)
National Institutes of Health
Grant: 3UM1AI068614-15S2
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
FWCI
3.92
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals